Experimental angina treatment rejected by the FDABMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7104.327c (Published 09 August 1997) Cite this as: BMJ 1997;315:327
- Deborah Josefson
- San Francisco
An advisory committee of the Food and Drug Administration has recommended rejecting transmyocardial revascularisation as a treatment for angina. Currently an experimental treatment of last resort, the two hour procedure entails drilling small holes by laser into the heart in the hope that revascularisation of the myocardium will occur.
PLC systems, manufacturer of the laser used in transmyocardial revascularisation, had applied for the Food and Drug Administration's approval of the device and the procedure itself. Dr Mahmood Mirhoseini of St Luke's Medical Center in Milwaukee, Wisconsin, pioneered the treatment in an effort to provide an alternative method of myocardial perfusion in patients with ischaemic heart and coronary artery disease. It was developed after several investigators showed that reptiles and some fish achieve myocardial perfusion through direct diffusion of oxygen rich blood from the ventricular cavity into the surrounding cardiac muscle. Researchers believed that by surgically …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial